Drug intelligence / Profile preview

BrightLight

Development stage: Unknown
Lead developer: Johnson & Johnson

Overview

BrightLight is an investigational pharmaceutical drug developed by Intra-Cellular Therapies, currently in late-stage development with Phase 3 trials underway. It is being investigated for the treatment of central nervous system (CNS) disorders, specifically schizophrenia. Johnson & Johnson is in the process of acquiring Intra-Cellular Therapies, which includes BrightLight in its pipeline, indicating a strategic expansion into CNS and mental health.

Targets

SERT (Sodium-dependent serotonin transporter)HTR2A (Serotonin receptor 5-HT2A)HTR7 (5-hydroxytryptamine receptor 7)DRD2 (Dopamine D2 Receptor)HTR2C (5-hydroxytryptamine 2C receptor)

Beyond the preview

Go deeper on BrightLight.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BrightLight.

Explore the full profile